Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.54 |
| ▸ | F10 | P00742 | 11/20 | 0.54 |
| ▸ | F2 | P00734 | 4/20 | 0.54 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.53 |
| ▸ | PYGL | P06737 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083427 | 1.00 | SMYD3 (0.54) | SMYD3F10F2EHMT2PYGL | |
| SCHEMBL3335060 | 1.00 | SMYD3 (0.54) | SMYD3F10F2EHMT2PYGL | |
| SCHEMBL4083426 | 1.00 | SMYD3 (0.54) | SMYD3F10F2EHMT2PYGL | |
| SCHEMBL4095864 | 1.00 | SMYD3 (0.54) | SMYD3F10F2EHMT2PYGL | |
| SCHEMBL3335058 | 1.00 | SMYD3 (0.54) | SMYD3F10F2EHMT2PYGL | |
| SCHEMBL4095868 | 1.00 | SMYD3 (0.54) | SMYD3F10F2EHMT2PYGL | |
| SCHEMBL27637674 | 0.90 | SMYD3 (0.51) | SMYD3F10F2EHMT2PYGL | |
| SCHEMBL11960497 | 0.88 | PYGL (0.50) | SMYD3F10F2EHMT2PYGL | |
| SCHEMBL4089091 | 0.88 | SMYD3 (0.48) | SMYD3F10F2EHMT2PYGL | |
| SCHEMBL2712286 | 0.88 | F10 (0.58) | SMYD3F10F2EHMT2PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | SMYD3 4107/4885F10 152/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.